200 related articles for article (PubMed ID: 12543948)
21. Good news for gene therapy.
Berns A
N Engl J Med; 2004 Apr; 350(16):1679-80. PubMed ID: 15084702
[No Abstract] [Full Text] [Related]
22. US authorities uphold suspension of SCID gene therapy.
Fox JL
Nat Biotechnol; 2003 Mar; 21(3):217. PubMed ID: 12610555
[No Abstract] [Full Text] [Related]
23. Clinical research. Gene therapy a suspect in leukemia-like disease.
Marshall E
Science; 2002 Oct; 298(5591):34-5. PubMed ID: 12364755
[No Abstract] [Full Text] [Related]
24. Safety panel backs principle of gene-therapy trials.
Check E
Nature; 2002 Dec; 420(6916):595. PubMed ID: 12478252
[No Abstract] [Full Text] [Related]
25. French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy.
European Society of Gene Therapy
J Gene Med; 2003 Jan; 5(1):82-4. PubMed ID: 12516054
[No Abstract] [Full Text] [Related]
26. Bubble babies and bathwater.
Nat Biotechnol; 2002 Nov; 20(11):1063. PubMed ID: 12410236
[No Abstract] [Full Text] [Related]
27. Risks and benefits of gene therapy.
Noguchi P
N Engl J Med; 2003 Jan; 348(3):193-4. PubMed ID: 12529458
[No Abstract] [Full Text] [Related]
28. Selective growth advantage of wild-type lymphocytes in X-linked SCID recipients.
Kume A; Koremoto M; Mizukami H; Okada T; Hanazono Y; Sugamura K; Ozawa K
Bone Marrow Transplant; 2002 Jul; 30(2):113-8. PubMed ID: 12132050
[TBL] [Abstract][Full Text] [Related]
29. Genes can come true.
Phillips H
New Sci; 2002 Nov; 176(2371):30-3. PubMed ID: 12731520
[No Abstract] [Full Text] [Related]
30. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.
Hacein-Bey-Abina S; von Kalle C; Schmidt M; Le Deist F; Wulffraat N; McIntyre E; Radford I; Villeval JL; Fraser CC; Cavazzana-Calvo M; Fischer A
N Engl J Med; 2003 Jan; 348(3):255-6. PubMed ID: 12529469
[No Abstract] [Full Text] [Related]
31. SCID trials to remain on the 'bubble'.
Mandavilli A
Nat Med; 2003 Mar; 9(3):251. PubMed ID: 12612562
[No Abstract] [Full Text] [Related]
32. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy: shining hopes dented - but not dashed.
Check E
Nature; 2002 Dec 19-26; 420(6917):735. PubMed ID: 12490910
[No Abstract] [Full Text] [Related]
34. Gene therapy: X-SCID transgene leukaemogenicity.
Thrasher AJ; Gaspar HB; Baum C; Modlich U; Schambach A; Candotti F; Otsu M; Sorrentino B; Scobie L; Cameron E; Blyth K; Neil J; Abina SH; Cavazzana-Calvo M; Fischer A
Nature; 2006 Sep; 443(7109):E5-6; discussion E6-7. PubMed ID: 16988659
[TBL] [Abstract][Full Text] [Related]
35. The trials of gene therapy.
Nature; 2002 Nov; 420(6912):107. PubMed ID: 12432344
[No Abstract] [Full Text] [Related]
36. A tragic setback.
Check E
Nature; 2002 Nov; 420(6912):116-8. PubMed ID: 12432357
[No Abstract] [Full Text] [Related]
37. Efficacy of gene therapy for SCID is being confirmed.
Cavazzana-Calvo M; Fischer A
Lancet; 2004 Dec 18-31; 364(9452):2155-6. PubMed ID: 15610783
[No Abstract] [Full Text] [Related]
38. American Society of Gene Therapy meeting. Retroviral vectors: a double-edged sword.
Kaiser J
Science; 2005 Jun; 308(5729):1735-6. PubMed ID: 15961648
[No Abstract] [Full Text] [Related]
39. Looking into the safety of AAV vectors.
Kay MA; Nakai H
Nature; 2003 Jul; 424(6946):251. PubMed ID: 12867952
[No Abstract] [Full Text] [Related]
40. The future of gene therapy.
Cavazzana-Calvo M; Thrasher A; Mavilio F
Nature; 2004 Feb; 427(6977):779-81. PubMed ID: 14985734
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
